(RTTNews) – AstraZeneca PLC (AZN) announced on Monday that a complex of its Covid-19 vaccine, AZD1222, has begun in the United States.
Participants are randomly assigned to obtain two doses of AZD1222 or saline control, 4 weeks apart, with two times as many participants receiving the vaccine as saline control, the company said.
In July, AstraZeneca published the provisional effects of the existing Phase I/II candidate vaccine with intelligent immune responses opposed to SARS-CoV-2 appearing in all participants.
Advanced studies on AZD1222 are already underway in the UK, Brazil and South Africa, and additional trials are expected to begin in Japan and Russia.